Enter the “director of prostate imaging” (at least at some centers)

As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …

Axumin-enhanced PET scans becoming more widely available

Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …

Comparison of gallium-68- and choline-C11-based PET/CT scanning in high-risk and progressive prostate cancers

The question of how much better the varied, new forms of imaging will be in the evaluation of patients with higher-risk prostate cancer both before and after their treatment is a currently “hot topic” in the world of prostate cancer. … READ MORE …

Will restriction spectrum imaging replace multiparametric MRI?

Researchers at the University of California San Diego have developed a new kind of MRI called restriction spectrum imaging MRI or just RSI-MRI that seems to discriminate among Gleason grades 3, 4, and 5 with unmatched geographic precision. … READ MORE …

New fluorine-18-based imaging agent approved in USA

Last Friday the US Food and Drug Administration (FDA) last Friday approved a new type of imaging agent for use in PET/CT scans for men with suspected prostate cancer recurrence after earlier treatment. … READ MORE …

What’s happening at the annual EAU meeting in Munich?

So our friends at UroToday have started providing reports on the key presentations that are being given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. Here are links to some interesting reports … READ MORE …

CureTalk program on imaging and genomics with Dr. David Lee

Yesterday evening we held a CureTalk program on the roles of new imaging and genomic/genetic tests in the diagnosis, work-up, and prognosis of prostate cancer with Dr. David Lee of the University of Pennsylvania. … READ MORE …